Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + irinotecan + nedaplatin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of nedaplatin (a second-generation platinum derivative), irinotecan (a topoisomerase I inhibitor), and gefitinib (an EGFR tyrosine kinase inhibitor). This regimen has been studied in Phase II clinical trials for the treatment of unresectable non-small cell lung cancer (NSCLC), particularly in elderly patients. The treatment protocol typically involves administering nedaplatin and irinotecan as combination chemotherapy followed by gefitinib.
02
Targets
Beyond the preview
Go deeper on gefitinib + irinotecan + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + irinotecan + nedaplatin.